Our findings of the primary endpoint outcome demonstrated that COVID-19 patients with elevated cTnT levels had a higher prevalence of baseline cardiovascular conditions, such as atrial fibrillation, myocarditis, and heart failure. The gene discussed is TNNT2; the disease is myocarditis.